VRCAVerrica Pharmaceuticals Inc.

Nasdaq verrica.com


$ 9.04 $ 0.28 (3.19 %)    

Wednesday, 22-May-2024 15:59:55 EDT
QQQ $ 454.82 $ -0.09 (-0.02 %)
DIA $ 398.57 $ -2.12 (-0.53 %)
SPY $ 530.36 $ -1.53 (-0.29 %)
TLT $ 91.26 $ 0.11 (0.12 %)
GLD $ 225.37 $ 0.00 (0 %)
$ 9.05
$ 9.34
$ 0.00 x 0
$ 0.00 x 0
$ 9.00 - $ 9.35
$ 2.86 - $ 11.41
141,985
na
420.68M
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-06-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 03-02-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-07-2021 03-31-2021 10-Q
14 03-17-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-13-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 03-07-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-buy-on-verrica-pharmaceuticals-maintains-16-price-target

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $16 price target.

 hc-wainwright--co-maintains-buy-on-verrica-pharmaceuticals-raises-price-target-to-14

HC Wainwright & Co. analyst Oren Livnat maintains Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and raises the price ...

 needham-maintains-buy-on-verrica-pharmaceuticals-raises-price-target-to-16

Needham analyst Serge Belanger maintains Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and raises the price target from $...

 needham-reiterates-buy-on-verrica-pharmaceuticals-maintains-8-price-target

Needham reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $8 price target.

 verrica-pharmaceuticals-lead-product-ycanth-has-received-new-chemical-entity-status-and-a-listing-in-the-orange-book-from-the-fda-providing-a-minimum-of-five-years-of-regulatory-exclusivity

NCE status provides a minimum of five years of regulatory exclusivity The Company's U.S. patents and pending patent appl...

 needham-reiterates-buy-on-verrica-pharmaceuticals-maintains-8-price-target

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $8 price target.

 hc-wainwright--co-maintains-buy-on-verrica-pharmaceuticals-raises-price-target-to-13

HC Wainwright & Co. analyst Oren Livnat maintains Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and raises the price ...

 verrica-pharmaceuticals-q4-eps-053-inline-sales-199m-beat-91000k-estimate

Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.53) per share which met the analyst consensus estimate. ...

 earnings-scheduled-for-february-29-2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

 top-4-health-care-stocks-that-may-crash-this-month

As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION